Kids With Food Allergies is sharing this press release from DBV Technologies to bring you the latest research news quickly.
DBV Technologies Provides Update on Regulatory Status of Viaskin Peanut for the Treatment of PeanutAllergic Children 4 to 11 Years of Age
Progress made to date to enable BLA resubmission in Q3 2019
Company to hold conference call today, February 13th, at 4:30 ET / 22:30 CET
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market:
DBVT), a clinical-stage biopharmaceutical company, today announced that its
planned resubmission of the Biologics License Application (BLA) to the U.S. Food
and Drug Administration (FDA) for Viaskin Peanut in the treatment of peanut-allergic children 4 to 11 years of age is anticipated in the third quarter of 2019.
“We appreciate the detailed feedback the FDA provided in December 2018, which
has allowed us to make meaningful headway in addressing the information
requests needed for a BLA resubmission,” said Daniel Tasse, Chief Executive Officer of DBV Technologies. “We are working diligently on our Viaskin Peanut BLA,
bringing us one step closer to potentially providing an FDA-approved treatment
for peanut-allergic children and their families.”
In December 2018, DBV voluntarily withdrew its BLA for Viaskin Peanut following
correspondence with the FDA regarding additional data needs on manufacturing
procedures and quality controls. Based on the progress in addressing the FDA’s
guidance, the Company anticipates compiling the required information for the
resubmission of its Viaskin Peanut BLA in the third quarter of 2019.
Viaskin Peanut previously received Breakthrough and Fast Track designations for
the treatment of peanut-allergic children from the FDA in 2015 and 2012,
Conference Call Information
The Company will host a conference call to discuss this update on February 13th, 2019 at 4:30 PM ET (22:30 CET). The conference call may be accessed by dialing 1 (888) 424-8151 for U.S. callers and 1 (847) 585-4422 for international callers. The passcode for the call is 6564 506#. A replay of the call will be available for 30 days following the call. The replay number is 1 (888) 843-7419 in the United States and 1 (630) 652-Montrouge, France, February 13, 2019 3042 internationally. The conference call ID number is 6564 506#.
About DBV Technologies
DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potentia applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the Company is dedicated to
safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its
platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, Summit, NJ and New York, NY. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company’s ADSs (each representing one-half of one ordinary share) are
traded on the Nasdaq Global Select Market (Ticker: DBVT).
DBV Media Contact
VP, Global Corporate Communications